Cargando…
Identification of Novel Hemostatic Biomarkers of Adverse Clinical Events in Patients Implanted With a Continuous-Flow Left Ventricular Assist Device
Heart failure affects over 5 million people in the United States. Its rising prevalence and the limited supply of donor hearts is increasing the use of mechanical cardiac support with the implantation of continuous-flow ventricular assist devices (CF-VAD). Patients with CF-VAD implants are at risk o...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714718/ https://www.ncbi.nlm.nih.gov/pubmed/29552914 http://dx.doi.org/10.1177/1076029618760235 |
_version_ | 1783447107419504640 |
---|---|
author | McClane, Nathan Jeske, Walter Walenga, Jeanine M. Escalante, Vicki Hoppensteadt, Debra Schwartz, Jeffrey Bakhos, Mamdouh |
author_facet | McClane, Nathan Jeske, Walter Walenga, Jeanine M. Escalante, Vicki Hoppensteadt, Debra Schwartz, Jeffrey Bakhos, Mamdouh |
author_sort | McClane, Nathan |
collection | PubMed |
description | Heart failure affects over 5 million people in the United States. Its rising prevalence and the limited supply of donor hearts is increasing the use of mechanical cardiac support with the implantation of continuous-flow ventricular assist devices (CF-VAD). Patients with CF-VAD implants are at risk of complications, specifically adverse hemostatic events such as nonsurgical bleeding and thrombosis. Development of a pump thrombus requires clinical intervention and/or surgical replacement significantly increasing the risk of patient morbidity and mortality. Identification of biomarkers for these events could improve current risk assessment models, subsequent treatment, and quality of life prognoses for VAD-implanted patients. The standard means for identifying thrombus in VAD patients is currently limited to monitoring levels of lactate dehydrogenase (>2× upper limit of normal), which is incapable of predicting a future event, but describes the risk of a present thrombus. Surface-enhanced laser desorption ionization time-of-flight mass spectrometry is a technique used to identify biomarkers. In this study, 3 groups of unique peaks were identified in plasma from patients with left ventricular assist devices: 8.1-kDa, 11.7-kDa, and a 15.2-/16.1-kDa pair. Unique correlations were found for each peak, respectively, with microparticles (MPs) and MP procoagulant activity, C-reactive protein, and MP-tissue factor. Furthermore, the use of 8.1-kDa peaks may be able to differentiate thrombotic events from other hemostatic events. |
format | Online Article Text |
id | pubmed-6714718 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-67147182019-09-04 Identification of Novel Hemostatic Biomarkers of Adverse Clinical Events in Patients Implanted With a Continuous-Flow Left Ventricular Assist Device McClane, Nathan Jeske, Walter Walenga, Jeanine M. Escalante, Vicki Hoppensteadt, Debra Schwartz, Jeffrey Bakhos, Mamdouh Clin Appl Thromb Hemost Original Articles Heart failure affects over 5 million people in the United States. Its rising prevalence and the limited supply of donor hearts is increasing the use of mechanical cardiac support with the implantation of continuous-flow ventricular assist devices (CF-VAD). Patients with CF-VAD implants are at risk of complications, specifically adverse hemostatic events such as nonsurgical bleeding and thrombosis. Development of a pump thrombus requires clinical intervention and/or surgical replacement significantly increasing the risk of patient morbidity and mortality. Identification of biomarkers for these events could improve current risk assessment models, subsequent treatment, and quality of life prognoses for VAD-implanted patients. The standard means for identifying thrombus in VAD patients is currently limited to monitoring levels of lactate dehydrogenase (>2× upper limit of normal), which is incapable of predicting a future event, but describes the risk of a present thrombus. Surface-enhanced laser desorption ionization time-of-flight mass spectrometry is a technique used to identify biomarkers. In this study, 3 groups of unique peaks were identified in plasma from patients with left ventricular assist devices: 8.1-kDa, 11.7-kDa, and a 15.2-/16.1-kDa pair. Unique correlations were found for each peak, respectively, with microparticles (MPs) and MP procoagulant activity, C-reactive protein, and MP-tissue factor. Furthermore, the use of 8.1-kDa peaks may be able to differentiate thrombotic events from other hemostatic events. SAGE Publications 2018-03-18 2018-09 /pmc/articles/PMC6714718/ /pubmed/29552914 http://dx.doi.org/10.1177/1076029618760235 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Articles McClane, Nathan Jeske, Walter Walenga, Jeanine M. Escalante, Vicki Hoppensteadt, Debra Schwartz, Jeffrey Bakhos, Mamdouh Identification of Novel Hemostatic Biomarkers of Adverse Clinical Events in Patients Implanted With a Continuous-Flow Left Ventricular Assist Device |
title | Identification of Novel Hemostatic Biomarkers of Adverse Clinical Events in Patients Implanted With a Continuous-Flow Left Ventricular Assist Device |
title_full | Identification of Novel Hemostatic Biomarkers of Adverse Clinical Events in Patients Implanted With a Continuous-Flow Left Ventricular Assist Device |
title_fullStr | Identification of Novel Hemostatic Biomarkers of Adverse Clinical Events in Patients Implanted With a Continuous-Flow Left Ventricular Assist Device |
title_full_unstemmed | Identification of Novel Hemostatic Biomarkers of Adverse Clinical Events in Patients Implanted With a Continuous-Flow Left Ventricular Assist Device |
title_short | Identification of Novel Hemostatic Biomarkers of Adverse Clinical Events in Patients Implanted With a Continuous-Flow Left Ventricular Assist Device |
title_sort | identification of novel hemostatic biomarkers of adverse clinical events in patients implanted with a continuous-flow left ventricular assist device |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714718/ https://www.ncbi.nlm.nih.gov/pubmed/29552914 http://dx.doi.org/10.1177/1076029618760235 |
work_keys_str_mv | AT mcclanenathan identificationofnovelhemostaticbiomarkersofadverseclinicaleventsinpatientsimplantedwithacontinuousflowleftventricularassistdevice AT jeskewalter identificationofnovelhemostaticbiomarkersofadverseclinicaleventsinpatientsimplantedwithacontinuousflowleftventricularassistdevice AT walengajeaninem identificationofnovelhemostaticbiomarkersofadverseclinicaleventsinpatientsimplantedwithacontinuousflowleftventricularassistdevice AT escalantevicki identificationofnovelhemostaticbiomarkersofadverseclinicaleventsinpatientsimplantedwithacontinuousflowleftventricularassistdevice AT hoppensteadtdebra identificationofnovelhemostaticbiomarkersofadverseclinicaleventsinpatientsimplantedwithacontinuousflowleftventricularassistdevice AT schwartzjeffrey identificationofnovelhemostaticbiomarkersofadverseclinicaleventsinpatientsimplantedwithacontinuousflowleftventricularassistdevice AT bakhosmamdouh identificationofnovelhemostaticbiomarkersofadverseclinicaleventsinpatientsimplantedwithacontinuousflowleftventricularassistdevice |